Efficacy of Levosimendan in the Treatment of Patients With Severe Septic Cardiomyopathy
Authors' conclusion
Compared with dobutamine, levosimendan was more effective at improving cardiac function, reducing myocardial injury, and reducing mechanical ventilation time in patients with severe septic cardiomyopathy.
Study context
- Population
- Patients with severe septic cardiomyopathy (LVEF ≤35%), Department of Critical Medicine, Baoding, China, September 2018 to September 2021
- Participants
- 30 patients
- Comparison
- Levosimendan vs dobutamine
- Primary endpoint
- 28-day mortality
- Follow-up
- 28 days
Methodological detailsprospective, single-blind
- Prospective
- Single-blind
Primary result
As reported in the abstract
- Difference in 28-day mortality between groups not statistically significant
Further findings
Cardiac index, LVEF, stroke volume index (SVI), fluid volume, norepinephrine dose · 24th hour after treatment
- CI, LVEF, SVI and fluid volume higher, norepinephrine dose lower in the levosimendan group vs the dobutamine group
Cardiac troponin I · third day of treatment
- Lower in the levosimendan group vs the dobutamine group
Intensive care unit (ICU) stay and ICU treatment cost
- Differences between groups not statistically significant
Ventilator application time
- Significantly shorter in the levosimendan group vs the dobutamine group
Original publication
Efficacy of Levosimendan in the Treatment of Patients With Severe Septic Cardiomyopathy. J Cardiothorac Vasc Anesth. Published 6 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →